{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:05:24Z","timestamp":1794661524648,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["2022\/14232\/ZONMW"],"award-info":[{"award-number":["2022\/14232\/ZONMW"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["A4\/5-CR179"],"award-info":[{"award-number":["A4\/5-CR179"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["M4\/1\/2\/5-MIS\/BEJ"],"award-info":[{"award-number":["M4\/1\/2\/5-MIS\/BEJ"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK098263"],"award-info":[{"award-number":["R01DK098263"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["8040-24"],"award-info":[{"award-number":["8040-24"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013845","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","award":["F\/2020\/1440"],"award-info":[{"award-number":["F\/2020\/1440"]}],"id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Enhanced glycolysis plays a pivotal role in fueling the aberrant proliferation, survival and therapy resistance of acute myeloid leukemia (AML) cells. Here, we aimed to elucidate the extent of glycolysis dependence in AML by focusing on the role of lactate dehydrogenase A (LDHA), a key glycolytic enzyme converting pyruvate to lactate coupled with the recycling of NAD\n                      <jats:sup>+<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the glycolytic activity of primary AML patient samples to protein levels of metabolic enzymes involved in central carbon metabolism including glycolysis, glutaminolysis and the tricarboxylic acid cycle. To evaluate the therapeutic potential of targeting glycolysis in AML, we treated AML primary patient samples and cell lines with pharmacological inhibitors of LDHA and monitored cell viability. Glycolytic activity and mitochondrial oxygen consumption were analyzed in AML patient samples and cell lines post-LDHA inhibition. Perturbations in global metabolite levels and redox balance upon LDHA inhibition in AML cells were determined by mass spectrometry, and ROS levels were measured by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among metabolic enzymes, we found that LDHA protein levels had the strongest positive correlation with glycolysis in AML patient cells. Blocking LDHA activity resulted in a strong growth inhibition and cell death induction in AML cell lines and primary patient samples, while healthy hematopoietic stem and progenitor cells remained unaffected. Investigation of the underlying mechanisms showed that LDHA inhibition reduces glycolytic activity, lowers levels of glycolytic intermediates, decreases the cellular NAD\n                      <jats:sup>+<\/jats:sup>\n                      pool, boosts OXPHOS activity and increases ROS levels. This increase in ROS levels was however not linked to the observed AML cell death. Instead, we found that LDHA is essential to maintain a correct NAD\n                      <jats:sup>+<\/jats:sup>\n                      \/NADH ratio in AML cells. Continuous intracellular NAD\n                      <jats:sup>+<\/jats:sup>\n                      supplementation via overexpression of water-forming NADH oxidase from\n                      <jats:italic>Lactobacillus brevis<\/jats:italic>\n                      in AML cells effectively increased viable cell counts and prevented cell death upon LDHA inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Collectively, our results demonstrate that AML cells critically depend on LDHA to maintain an adequate NAD\n                      <jats:sup>+<\/jats:sup>\n                      \/NADH balance in support of their abnormal glycolytic activity and biosynthetic demands, which cannot be compensated for by other cellular NAD\n                      <jats:sup>+<\/jats:sup>\n                      recycling systems. These findings also highlight LDHA inhibition as a promising metabolic strategy to eradicate leukemic cells.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40170-025-00392-4","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:07:10Z","timestamp":1747649230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lactate dehydrogenase A-coupled NAD+ regeneration is critical for acute myeloid leukemia cell survival"],"prefix":"10.1186","volume":"13","author":[{"given":"Ay\u015feg\u00fcl","family":"Erdem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9l\u00e9na","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caligiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"van Gastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"22","key":"392_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, et al. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"15","key":"392_CR2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMc1310365","volume":"369","author":"CA Miller","year":"2013","unstructured":"Miller CA, Wilson RK, Ley TJ. Genomic landscapes and clonality of de Novo AML. N Engl J Med. 2013;369(15):1473.","journal-title":"N Engl J Med"},{"key":"392_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/BF01504608","volume":"12","author":"O Warburg","year":"1924","unstructured":"Warburg O. \u00dcber Den Stoffwechsel der carcinomzelle. Naturwissenschaften. 1924;12:1131\u20137.","journal-title":"Naturwissenschaften"},{"issue":"10","key":"392_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141(10):1119\u201335.","journal-title":"Blood"},{"issue":"5","key":"392_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724\u2013e7404.","journal-title":"Cancer Cell"},{"issue":"5","key":"392_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748\u2013e7644.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"392_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23\u201337.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"392_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"N van Gastel","year":"2020","unstructured":"van Gastel N, et al. Induction of a timed metabolic collapse to overcome Cancer chemoresistance. Cell Metab. 2020;32(3):391\u2013e4036.","journal-title":"Cell Metab"},{"issue":"7","key":"392_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, et al. Chemotherapy-Resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716\u201335.","journal-title":"Cancer Discov"},{"issue":"1","key":"392_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41467-022-28737-3","volume":"13","author":"A Erdem","year":"2022","unstructured":"Erdem A, et al. The glycolytic gatekeeper PDK1 defines different metabolic States between genetically distinct subtypes of human acute myeloid leukemia. Nat Commun. 2022;13(1):1105.","journal-title":"Nat Commun"},{"issue":"1","key":"392_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/s41467-022-29639-0","volume":"13","author":"A Erdem","year":"2022","unstructured":"Erdem A, et al. Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability. Nat Commun. 2022;13(1):2013\u2013p.","journal-title":"Nat Commun"},{"issue":"4","key":"392_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2018.08.014","volume":"34","author":"B de Boer","year":"2018","unstructured":"de Boer B, et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell. 2018;34(4):674\u2013e6898.","journal-title":"Cancer Cell"},{"issue":"4","key":"392_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cmet.2018.11.013","volume":"29","author":"X Hao","year":"2019","unstructured":"Hao X, et al. Metabolic imaging reveals a unique preference of symmetric cell division and homing of Leukemia-Initiating cells in an endosteal niche. Cell Metab. 2019;29(4):950\u2013e9656.","journal-title":"Cell Metab"},{"issue":"15","key":"392_CR14","doi-asserted-by":"publisher","first-page":"e35721","DOI":"10.1016\/j.heliyon.2024.e35721","volume":"10","author":"Y Yang","year":"2024","unstructured":"Yang Y, Pu J, Yang Y. Glycolysis and chemoresistance in acute myeloid leukemia. Heliyon. 2024;10(15):e35721.","journal-title":"Heliyon"},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.leukres.2023.107059","volume":"128","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Glucose induced-AKT\/mTOR activation accelerates Glycolysis and promotes cell survival in acute myeloid leukemia. Leuk Res. 2023;128:107059.","journal-title":"Leuk Res"},{"issue":"8","key":"392_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.58","volume":"30","author":"M Braun","year":"2016","unstructured":"Braun M, et al. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4\/mTOR axis. Leukemia. 2016;30(8):1788\u201392.","journal-title":"Leukemia"},{"issue":"1","key":"392_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli I, et al. Mubritinib targets the Electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell. 2019;36(1):84\u2013e998.","journal-title":"Cancer Cell"},{"issue":"7","key":"392_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24(7):1036\u201346.","journal-title":"Nat Med"},{"issue":"6","key":"392_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2014.07.048","volume":"158","author":"Y-H Wang","year":"2014","unstructured":"Wang Y-H, et al. Cell-State-Specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014;158(6):1309\u201323.","journal-title":"Cell"},{"key":"392_CR20","doi-asserted-by":"crossref","unstructured":"Preis JR et al. Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler. bioRxiv, 2024: p. 2024.11.04.621801.","DOI":"10.1101\/2024.11.04.621801"},{"issue":"5","key":"392_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32(5):829\u2013e8439.","journal-title":"Cell Metab"},{"issue":"12","key":"392_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1042\/BCJ20220170","volume":"479","author":"M Johanns","year":"2022","unstructured":"Johanns M, et al. Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other Pharmacological AMPK activators. Biochem J. 2022;479(12):1317\u201336.","journal-title":"Biochem J"},{"issue":"1","key":"392_CR23","doi-asserted-by":"publisher","first-page":"G97","DOI":"10.1152\/ajpgi.00093.2017","volume":"314","author":"R Masia","year":"2018","unstructured":"Masia R, et al. Live cell imaging of cytosolic NADH\/NAD\u2009+\u2009ratio in hepatocytes and liver slices. Am J Physiology-Gastrointestinal Liver Physiol. 2018;314(1):G97\u2013108.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"6282","key":"392_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1126\/science.aad4017","volume":"352","author":"DV Titov","year":"2016","unstructured":"Titov DV, et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+\/NADH ratio. Science. 2016;352(6282):231\u20135.","journal-title":"Science"},{"issue":"2","key":"392_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, et al. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"392_CR26","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","volume":"107","author":"A Le","year":"2010","unstructured":"Le A, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107(5):2037\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"392_CR27","doi-asserted-by":"publisher","first-page":"1269896","DOI":"10.3389\/fimmu.2023.1269896","volume":"14","author":"J Yong","year":"2023","unstructured":"Yong J, Cai S, Zeng Z. Targeting NAD\u2009+\u2009metabolism: dual roles in cancer treatment. Front Immunol. 2023;14:1269896.","journal-title":"Front Immunol"},{"issue":"10","key":"392_CR28","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.stem.2021.06.004","volume":"28","author":"A Subedi","year":"2021","unstructured":"Subedi A, et al. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell. 2021;28(10):1851\u2013e18678.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"392_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40364-024-00674-x","volume":"12","author":"C Ijurko","year":"2024","unstructured":"Ijurko C, et al. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia. Biomark Res. 2024;12(1):128.","journal-title":"Biomark Res"},{"issue":"4","key":"392_CR30","doi-asserted-by":"publisher","first-page":"e2111338119","DOI":"10.1073\/pnas.2111338119","volume":"119","author":"IP Heremans","year":"2022","unstructured":"Heremans IP, et al. Parkinson\u2019s disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite. Proc Natl Acad Sci U S A. 2022;119(4):e2111338119.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00392-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:07:12Z","timestamp":1747649232000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/10.1186\/s40170-025-00392-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00392-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.03.641255","asserted-by":"object"}]},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}